Divine Aleru, Microbiome Signatures Research Coordinator

Dietary copper-fructose interactions in rats depleted Akkermansia, shifted Firmicutes families, weakened tight junctions and goblet cells, and raised liver injury signals, defining a dysbiosis–barrier–liver axis.

Dietary copper effect on intestinal microbiota in weaned piglets increased E. coli abundance and raised ciprofloxacin and chloramphenicol resistance, while shifting key metabolic pathways without growth benefit.

Copper and zinc toxicity in innate immunity drives early control of bacterial pathogens and shapes mucosal niches. The review links host metal routing and microbial export genes to killing, virulence, and microbiome shifts.

Copper treatment of sepsis links host copper delivery, microbial copper genes, and cell death pathways. The review highlights biomarker value and careful therapeutic targeting to aid control of infection while limiting tissue injury.

This review explores the critical role of copper in microbial pathogenesis, focusing on how the host uses it as an antimicrobial weapon and how pathogens resist Cu toxicity. It suggests potential therapeutic avenues targeting Cu resistance mechanisms.

This review explores copper’s role in microbial pathogenesis, highlighting its use by hosts as an antimicrobial weapon and the resistance mechanisms developed by pathogens. It discusses copper’s involvement in immune defense and fungal virulence, offering insights into potential therapeutic strategies.

Overview Copper (Cu) plays a dual role in microbial pathogenesis, acting both as an essential cofactor for critical bacterial enzymes and as a potent antimicrobial agent in the host’s immune response.[1] Many pathogens, including Mycobacterium tuberculosis, Pseudomonas aeruginosa, and Salmonella typhimurium, rely on copper for key enzymes such as cytochrome c oxidase and superoxide dismutase, […]

This review discusses advancements in chelation therapy for treating metal toxicity, focusing on chelating agents, combination therapies, and antioxidants. Key findings highlight the effectiveness of ADMSA and the potential for improved treatments.

This review discusses the detrimental effects of lead (Pb) exposure on gut microbiota, metabolism, and homeostasis, highlighting its role in metabolic and systemic disorders. It suggests interventions such as probiotics and dietary supplementation for mitigating Pb toxicity.

This study explores how lead exposure disrupts gut microbiota, leading to compromised gut health and systemic issues. It highlights the potential of probiotics and other interventions to restore balance and mitigate Pb toxicity.

The study investigates the effects of Nase I and proteinase K on the structure and composition of multispecies oral biofilms, finding that these enzymes disrupt biofilm integrity and shift microbial composition, potentially enhancing the effectiveness of antimicrobial treatments.

This study investigates PS-rich biofilm dynamics, showing how biofilm dispersal via Nase and PS-glycosidases influences microbial community structure and resilience. It highlights the role of commensal reseeding in restoring microbial balance after dispersal.

This study demonstrates that Vibrio harveyi regulates lead precipitation through quorum-sensing systems, particularly I1, I2, and a newly discovered I3, with implications for environmental bioremediation and microbial interactions in metal-contaminated environments.

This study demonstrates that I) and I) induce zntA expression in E. coli through R, highlighting the importance of A in metal resistance and the potential for therapeutic applications targeting metal transporters.

The study of the Ralstonia metallidurans pbr operon reveals mechanisms of lead resistance, highlighting I) uptake, efflux, and sequestration, and offering potential applications in bioremediation and therapeutic strategies for lead poisoning.

This review defines how lead binding in proteins drives host enzyme inhibition and signaling errors while microbial operons export and precipitate I), reshaping niche metal availability and competitive fitness.

A comprehensive review of Deferoxamine B metal chelator links siderophore chemistry, microbial uptake, and clinical chelation/imaging, highlighting speciation across metals—including I)—and implications for microbiome-related metal competition.

An in vivo radiotracer study defines lead absorption and excretion in the rat: duodenal, bile-modulated uptake; competition with Ca; iron deficiency–enhanced absorption; erythrocyte transport; early renal–hepatic handling; biliary plus urinary clearance; and bone storage.

A mechanistic review links heavy metals and human health to dysbiosis via protein-binding competition, redox injury, epithelial leak, and PS-driven inflammation, outlining organ toxicity and clinical chelation strategies.

This review discusses the toxicological impact of heavy metals like arsenic, cadmium, and mercury on human health, particularly their interaction with proteins and enzymes, leading to various disorders and potential carcinogenesis. Detoxification strategies and the importance of environmental cleanup are also highlighted.

The study highlights the cooperation between the A efflux pump and B phosphatase in the detoxification of lead, uncovering a novel mechanism for lead resistance in Cupriavidus metallidurans. This research suggests potential bioremediation applications and deeper insights into microbial heavy metal resistance mechanisms.

This study sheds light on the molecular mechanisms through which Cupriavidus metallidurans H34 regulates lead resistance, highlighting the role of the R protein and its interaction with the A promoter in response to I).

This study demonstrates that lead exposure disrupts the gut microbiome, reducing microbial diversity and impairing key metabolic pathways related to vitamin E, bile acids, nitrogen metabolism, and energy metabolism. These disruptions may contribute to lead toxicity and associated diseases.

This review maps mechanisms and taxa underlying lead bioremediation by bacteria, linking microbial toolkits (PS, phosphatases, sulfate reducers, IB-TPases, metallothioneins) to field performance and clinical microbiome relevance, and guiding signature curation and remediation design.

The review examines the neurotoxic effects of lead exposure, focusing on mechanisms such as ion mimicry, mitochondrial dysfunction, and neuroinflammation. It emphasizes the long-term impact of lead on cognitive function and behavior and discusses biomarkers for assessing lead exposure and its effects on the brain.

This review explores the molecular mechanisms of lead neurotoxicity, focusing on ion mimicry, mitochondrial dysfunction, oxidative stress, and neuroinflammation. The findings emphasize the long-term cognitive and behavioral effects of lead exposure, with implications for clinical intervention and microbiome-related research.

The review highlights the connection between lead exposure and osteoporosis risk in post-menopausal women, showing how lead release during bone turnover contributes to health complications. Strategies to reduce bone resorption during menopause can mitigate lead-related risks and improve health outcomes.

DC lowered the pediatric LRV to 3.5 µg/dL, enabling earlier action, clarifying disparities, and setting exposure tiers that should guide microbiome signature curation at contemporary low LLs.

Meta-analysis shows LAD polymorphism and lead interactions: LAD2 raises LL in workers, lowers chelatable lead, and slightly improves heme indices; bone lead is unchanged.

Clinician summary of prenatal lead exposure and gut microbiome links at age 9–11 in ROGRESS: negative mixture effects, trimester-specific taxa shifts, and a potential second-trimester sensitivity window.

A clinician-focused review updates present-day lead exposure risks and microbiome implications, contrasting older population metrics with PHERL’s prospective data and outlining how exposure tiers, co-exposures, and confounding shape credible microbiome–lead signatures.

Lead exposure has a profound effect on the microbiome, disrupting microbial diversity, immune responses, and contributing to the development of antimicrobial resistance (MR). Understanding how Pb interacts with microbial communities and impacts host-pathogen dynamics is essential for clinicians to mitigate long-term health risks and improve treatment strategies.

Ospemifene is an effective and safe treatment for menopausal vaginal dryness and dyspareunia, particularly in women with contraindications for estrogen therapy. It improves vaginal health without significantly affecting systemic hormone levels, providing an alternative treatment for genitourinary syndrome of menopause.

Ospemifene (60 mg/day) significantly reduces dyspareunia and improves vaginal health in postmenopausal women with vulvar and vaginal atrophy. It offers a non-estrogenic treatment option, especially for women who cannot use traditional hormone therapies.

What was studied?This study examined the systemic and local effects of vaginal dehydroepiandrosterone (HEA) in postmenopausal women, particularly those with a history of breast or gynecologic cancer. It evaluated the impact of vaginal HEA on hormone concentrations, markers of bone formation, and vaginal cytology, including pH and maturation index. The study aimed to assess the […]

This review underscores the importance of nutrition in managing menopausal symptoms and preventing chronic diseases. It highlights key nutrients such as calcium, vitamin D, and protein and promotes a balanced diet and regular physical activity as integral parts of menopausal health management.

This study reveals that higher levels of physical activity, especially during leisure time, are linked to reduced severity of menopausal symptoms, particularly urogenital and somato-vegetative issues. It suggests incorporating physical activity into the management plan for menopausal women, particularly postmenopausal women.

This review and meta-analysis demonstrate that psychological interventions, such as BT, BT, and T, can significantly reduce hot flash bother and menopausal symptoms. These findings are especially relevant for breast cancer survivors, offering a safe, non-hormonal alternative to RT.

Veozah (fezolinetant) is an effective non-hormonal treatment for menopause-related vasomotor symptoms. It works by targeting the neurokinin 3 receptor and offers a promising alternative to estrogen therapy with minimal side effects, making it suitable for women with contraindications to hormone treatments.

This study demonstrates that gabapentin 300 mg/day is as effective as estrogen 0.625 mg/day for reducing hot flashes in post-menopausal women. It provides a viable non-hormonal alternative with fewer side effects, making it a good option for women unable or unwilling to take estrogen.

This review confirms that SRIs and NRIs, particularly paroxetine and venlafaxine, are effective for managing hot flashes in menopausal women. These therapies provide an alternative to hormone replacement therapy, with minimal side effects and considerations for women with specific health concerns, like hypertension or a history of breast cancer.

This review assesses the safety of vaginal hormones and ERMs in treating genitourinary menopausal symptoms in breast cancer survivors. It finds no significant rise in serum estrogen levels or an increased risk of breast cancer recurrence, but more extensive studies are needed to confirm these findings.

This review highlights the lack of conclusive evidence on the safety of hormone replacement therapy (RT) in women treated for early-stage endometrial cancer. While a small study found no significant increase in cancer recurrence risk, the low quality of the evidence leaves uncertainty about the benefits and risks of RT use in these women.

This study shows that menopausal hormone therapy increases the risk of gallstones, especially with topical estrogen and tibolone. However, no increased risk for gallbladder cancer was found. These findings underscore the need for caution in prescribing hormone therapy, particularly for women with higher gallstone risk factors.

Long-term use of estrogen and estrogen-progestin therapies significantly increases the risk of endometrial cancer, particularly for women with lower MI. The risk is dose-dependent, with continuous-combined therapy having complex effects based on body weight.

This review offers updated guidance on the use of menopausal hormone therapy, highlighting its benefits when started early, particularly for women with low cardiovascular risk. It stresses the importance of individualized care and decision-making when considering T for managing menopausal symptoms.

This review investigates the stroke risk associated with hormonal therapies in postmenopausal women, comparing oral and transdermal estrogen formulations and highlighting the need for individualized treatment plans based on age and cardiovascular health.

This review explores the thrombosis risks of hormonal therapies, comparing various estrogen formulations and progestins. It emphasizes the need for personalized treatment based on thrombophilic risk factors, highlighting the safer options such as transdermal estrogen and progestin-only therapies.

This study explores estrogen’s effects on thrombosis risk in hormonal contraceptives and RT, highlighting mechanisms of action, the role of different estrogen doses, and the importance of individualized risk assessments in preventing thromboembolic events.

This study examines estrogen’s dual role in breast cancer, focusing on its effects on estrogen receptor-positive cancers and how different therapies, such as ERMs and aromatase inhibitors, mitigate risks while highlighting estrogen metabolism’s role in cancer risk.

The study emphasizes the risks and benefits of menopausal hormone therapy in managing vasomotor symptoms, osteoporosis, and cardiovascular health. It highlights the importance of timing, formulation, and route of administration in optimizing therapy for individual patients.

This review emphasizes the benefits and risks of HT in managing menopause symptoms, including the prevention of long-term conditions. It advocates for individualized treatment plans, especially focusing on the timing of initiation.

This guideline on menopausal symptom treatment prioritizes early initiation of hormone therapy, safe routes like transdermal estradiol, and vaginal care for genitourinary symptoms. It promotes a tailored approach considering cardiovascular and breast cancer risks.

The review defines menopause vasomotor symptoms treatment and microbiome relevance, favors timely hormone therapy and transdermal routes, details effective nonhormone options, and highlights neurokinin antagonists for fast relief while separating vasomotor and genitourinary care for microbiome-aware practice.

This review sets a simple plan for menopausal hormone therapy first-line management, favors transdermal routes when risk exists, and backs local therapy for genitourinary symptoms with clear links to vaginal ecosystem health.

The review shows that menopausal hormone therapy osteoporosis prevention lowers fractures when started near menopause, favors transdermal routes for safety, and maps ANKL–PG and cytokine shifts with clear microbiome relevance despite no direct microbiota data.

The guideline links menopausal hormone therapy guidelines and vaginal microbiome care to safer symptom control, better SM outcomes, and lower TI risk through local estrogen, with timing and route choices that manage vascular and endometrial risk.

The review defines progesterone endometrial tumor suppressor mechanisms, links receptor biology to therapy response, and outlines immune and barrier changes with clear microbiome relevance despite no direct taxa reporting.

This review links menopausal hormone therapy and vaginal microbiome care to safer symptom relief, bleeding control, and prevention. It favors transdermal estradiol and physiologic progestogens, and it highlights estriol plus lactobacilli for urogenital symptoms with minimal systemic exposure.

Hormone Replacement Therapy (RT) is one of the most effective treatments for women experiencing the symptoms of menopause, particularly vasomotor symptoms such as hot flashes and night sweats. But its benefits go beyond just symptom management. RT can also play a key role in improving vaginal health by alleviating dryness and discomfort, which are common complaints among women in menopause. Additionally, it helps prevent bone loss, significantly reducing the risk of osteoporosis and fractures, which are more common after menopause. Despite its many benefits, RT is not one-size-fits-all; it’s essential to tailor treatment based on individual health profiles, taking into account the risks like breast cancer, blood clots, and heart disease that come with prolonged use.

This study demonstrates the potent anticancer effects of a tumor-resident bacterial consortium in both immunocompetent and immunocompromised mice. The consortium induces tumor remission through selective thrombosis, necrosis, and biofilm formation, offering a promising drug-free strategy for cancer therapy with potential applications in treating solid tumors.

This review explores the role of microbiome-derived metabolites in inflammation-related cancer prevention and treatment, highlighting their dual effects in modulating inflammation and immune responses. It discusses key metabolites such as CFAs, polyamines, and bile acids, along with emerging therapies and the challenges in translating these findings into clinical practice.

This review explores the dual role of gut microbial metabolites in cancer, focusing on their anticancer and pro-carcinogenic effects. It emphasizes the potential of CFAs, bacteriocins, and dietary modifications in preventing and treating cancer, with a focus on colorectal cancer and other common malignancies.

The review examines the therapeutic potential of MT and next-generation microbiome therapies in treating metabolic disorders. It highlights the promising role of MT in restoring microbial balance and improving conditions like obesity and type 2 diabetes, though challenges remain in optimizing treatment protocols.

This review examines the immunomodulatory effects of probiotics, detailing how they enhance immune functions through interactions with immune cells in the gut. Probiotics help regulate cytokine release, boost A production, and support gut health, offering potential therapeutic benefits for immune disorders.

The review discusses the impact of gut microbiota on cancer therapy outcomes, focusing on chemotherapy and immunotherapy. It highlights how microbiota influences drug effectiveness and immune responses, emphasizing the potential of microbiota modulation for personalized treatment approaches.

This review emphasizes how gut microbiota influences cancer chemotherapy efficacy and toxicity. It discusses microbial species, metabolites, and strategies to optimize chemotherapy response, suggesting that microbiota modulation could improve treatment outcomes.

This review explores the dual role of the intratumoral microbiome in cancer, highlighting its impact on immune modulation and its potential as a target for innovative therapeutic strategies, including enhancing immunotherapy efficacy.

This review explores bacteria-based immunotherapy for cancer, highlighting how bacteria and their components modulate immune responses to enhance tumor targeting and therapy outcomes. It also discusses the potential for combining bacteria with traditional therapies like chemotherapy and immune checkpoint inhibitors.

This review explores the complex role of intratumoral microbiota in cancer, emphasizing their influence on immune responses and the potential for microbiome-based therapies in cancer immunotherapy. It discusses how specific microbes affect tumor progression and therapy resistance, offering insights into new treatment strategies.

This review explores the complex role of microbial metabolites in cancer, focusing on their impact on tumor initiation, progression, metastasis, and therapy response. It highlights how microbial products influence the tumor microenvironment and immune modulation, suggesting new avenues for cancer therapy.

This review explores the role of metabolism in cancer, highlighting how tumors adapt their metabolism to survive in the tumor microenvironment (ME) and how systemic metabolism influences treatment. It discusses metabolic reprogramming, immune competition, and the potential for targeted therapies to improve cancer treatment outcomes.

This review explores the complex relationship between inflammation and cancer, examining how chronic inflammation drives tumor initiation, progression, and metastasis. It highlights potential therapeutic strategies targeting inflammatory pathways to improve cancer treatment outcomes.

This review examines the role of intratumoral microbiota in cancer progression, immune modulation, and therapy resistance. It highlights microbial species involved in tumor growth and discusses the potential of microbiome-based treatments to improve cancer therapies.

This review investigates the spatial heterogeneity of intratumoral microbiota and its impact on cancer immunotherapy resistance. It highlights how microbial distribution within tumors influences immune responses and treatment efficacy, suggesting new strategies to overcome resistance and improve cancer therapy outcomes.

The review highlights the role of intratumoral microbiota in cancer initiation, progression, and therapy. It discusses the dual effects of these microbiota on immune responses, emphasizing their potential as diagnostic biomarkers and therapeutic targets in cancer treatment.

What was studied?This review article explores the role of intratumoral microbiota in cancer initiation, progression, and therapeutic responses. It highlights the complex interactions between microbial communities and the tumor microenvironment (ME) in various cancers, including colorectal, breast, pancreatic, and lung cancers. The review investigates how the presence of specific microbes within tumor tissues influences carcinogenesis, […]

This review explores the role of fungi in cancer progression, highlighting their impact on tumor development and immune responses. It emphasizes the potential for mycobiome-based cancer diagnostics and therapies, though challenges remain in understanding the exact mechanisms at play.

This review examines the role of intratumoral microbiota in colorectal cancer. It highlights how specific microbes influence tumor progression, immune responses, and therapy resistance, suggesting microbiota manipulation as a novel therapeutic approach.

This review explores how the oral microbiota influences cancer pathogenesis, highlighting its role in immune modulation, inflammation, and tumor progression. It emphasizes the potential of oral microbiota manipulation in improving cancer diagnosis and treatment outcomes.

This review explores how intratumoral microbiota influence cancer initiation, progression, and therapy. It highlights their roles in immune modulation, tumor growth, and therapeutic resistance, suggesting microbiome manipulation as a potential therapeutic strategy.

This review discusses how intratumoral microbiota influence cancer progression and therapy. It explores their roles in immune modulation, inflammation, and treatment resistance, and suggests microbiota manipulation as a potential therapeutic strategy for enhancing cancer treatment outcomes.

This review explores the role of intratumoral microbiota in cancer progression and immunity. It discusses how microbiota influence tumor behavior and therapy outcomes, suggesting potential therapeutic strategies and biomarkers for cancer treatment.

This review explores the role of intratumoral microbiota in cancer onset and progression, emphasizing their potential therapeutic applications in improving cancer treatment outcomes and offering new insights into cancer therapy.

With the growing understanding of the intratumoral microbiota’s influence on cancer progression, the next frontier in cancer therapy is microbiota-targeted interventions. By introducing beneficial microbes or altering existing microbial populations within tumors, therapies can be designed to modulate the immune system, promote tumor suppression, and improve drug efficacy. However, challenges remain in deciphering the complex relationships between microbes, tumor cells, and the immune system, necessitating more refined research methods and standardized approaches to translate these discoveries into clinical practice.

This review elucidates the hormonal and physiological mechanisms underpinning female puberty, detailing PG and PA axis activation, pubertal milestones, and regulatory factors, and discusses implications for clinical assessment and future microbiome research integration.

A comprehensive review of the hormonal regulation of puberty, diagnostic markers for distinguishing healthy from disordered puberty, and the implications for clinical practice, with emphasis on the endocrine framework relevant to future microbiome research.

This study identifies significant differences in age of menarche between rural and urban Nigerian girls, highlighting the influence of socioeconomic status and residence. Findings have implications for understanding pubertal timing and its potential links to the microbiome and long-term health risks.

A comprehensive review of evidence on the determinants and health implications of ages at menarche and menopause, highlighting their complex, independent origins and the influence of life-course genetic, environmental, and socioeconomic factors. No consistent direct association was found between the timing of menarche and menopause.

This commentary reviews the global neglect of menstrual health education at menarche, highlighting psychosocial and health consequences for girls. It advocates for standardized, early education and support to empower girls and improve reproductive health, with implications for microbiome-related outcomes.

This study explores the factors influencing age at menarche, menstrual knowledge, and hygiene practices among schoolgirls in Sharjah, AE. It highlights how socioeconomic factors, education, and hygiene practices impact menstrual health outcomes.

Menarche marks the first occurrence of menstruation, signaling a pivotal moment in a young girl’s transition to womanhood. Understanding this process helps to shed light on the hormonal, physical, and emotional changes that accompany puberty. Explore the importance of menarche, factors that influence its timing, and how it shapes women’s health throughout their lives.

This review explores the link between endometriosis and ovarian cancer, focusing on genetic mutations like RID1A, oxidative stress, and estrogen receptor loss, which contribute to the development of malignancy, particularly in the endometrioid and clear-cell subtypes.

This review explores the molecular pathogenesis of endometriosis-associated ovarian cancer, highlighting key genetic mutations, hormonal imbalances, and microRNA dysregulation that contribute to the disease. It discusses the potential for personalized treatment strategies based on molecular signatures to improve outcomes in affected patients.

This study examines the association between metformin use and survival outcomes in ovarian cancer patients. A significant survival benefit was found in diabetic patients, suggesting metformin may improve ovarian cancer prognosis, although further research is needed for non-diabetic patients.

This review explores the potential of repurposing non-oncological drugs for cancer therapy, highlighting their efficacy in preclinical studies and their mechanisms of action. It emphasizes the benefits of using established drugs to overcome cancer treatment challenges, particularly in overcoming drug resistance and reducing costs.

The review explores the potential of repurposing non-oncological drugs for ovarian cancer treatment, highlighting their ability to improve chemotherapy effectiveness and reduce treatment costs, with promising findings from preclinical studies and clinical trials.

What was studied?The study explores drug repositioning as a transformative strategy for ovarian cancer (C) treatment, highlighting the potential of repurposing existing drugs for more effective, accelerated, and cost-efficient therapies. The review focuses on in vitro experiments with various cancer cell lines and preclinical in vivo models to evaluate the efficacy of repurposed drugs, including […]

This review explores the role of targeted therapies in ovarian cancer treatment, focusing on the potential of angiogenesis inhibitors, ARP inhibitors, and folate receptor alpha inhibitors. While promising, further clinical trials and personalized approaches are necessary to enhance survival and treatment outcomes.

This review discusses the role of nutritional interventions in improving the nutritional status and clinical outcomes of women with ovarian cancer during treatment. It highlights the importance of personalized nutrition care and the need for more research to establish effective intervention strategies.